A Novel Antifungal Therapy

Current treatment for local and systemic fungal infections, including polyenes, azoles, and currently-approved echinocandins, have significant limitations. Toxicities, drug-drug interactions, low or variable exposure, daily intravenous administration and increasing resistance, are all the issues which will complicate the therapy today in the patients who are already inherently complex and extreme illness. This study is to treat fungal infections with a commensal bacteria in a suitable formulation